Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

High activation of STAT5A drives peripheral T-cell lymphoma and leukemia.

Maurer B, Nivarthi H, Wingelhofer B, Pham HTT, Schlederer M, Suske T, Grausenburger R, Schiefer AI, Prchal-Murphy M, Chen D, Winkler S, Merkel O, Kornauth C, Hofbauer M, Hochgatterer B, Hoermann G, Hoelbl-Kovacic A, Prochazkova J, Lobello C, Cumaraswamy AA, Latzka J, Kitzwögerer M, Chott A, Janikova A, Pospíšilova Š, Loizou JI, Kubicek S, Valent P, Kolbe T, Grebien F, Kenner L, Gunning PT, Kralovics R, Herling M, Müller M, Rülicke T, Sexl V, Moriggl R.

Haematologica. 2019 May 23. pii: haematol.2019.216986. doi: 10.3324/haematol.2019.216986. [Epub ahead of print]

2.

Twins with different personalities: STAT5B-but not STAT5A-has a key role in BCR/ABL-induced leukemia.

Kollmann S, Grundschober E, Maurer B, Warsch W, Grausenburger R, Edlinger L, Huuhtanen J, Lagger S, Hennighausen L, Valent P, Decker T, Strobl B, Mueller M, Mustjoki S, Hoelbl-Kovacic A, Sexl V.

Leukemia. 2019 Jul;33(7):1583-1597. doi: 10.1038/s41375-018-0369-5. Epub 2019 Jan 24.

3.

Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy.

Porpaczy E, Tripolt S, Hoelbl-Kovacic A, Gisslinger B, Bago-Horvath Z, Casanova-Hevia E, Clappier E, Decker T, Fajmann S, Fux DA, Greiner G, Gueltekin S, Heller G, Herkner H, Hoermann G, Kiladjian JJ, Kolbe T, Kornauth C, Krauth MT, Kralovics R, Muellauer L, Mueller M, Prchal-Murphy M, Putz EM, Raffoux E, Schiefer AI, Schmetterer K, Schneckenleithner C, Simonitsch-Klupp I, Skrabs C, Sperr WR, Staber PB, Strobl B, Valent P, Jaeger U, Gisslinger H, Sexl V.

Blood. 2018 Aug 16;132(7):694-706. doi: 10.1182/blood-2017-10-810739. Epub 2018 Jun 14. Erratum in: Blood. 2019 Feb 14;133(7):768.

PMID:
29907599
4.

Expansion of BCR/ABL1+ cells requires PAK2 but not PAK1.

Edlinger L, Berger-Becvar A, Menzl I, Hoermann G, Greiner G, Grundschober E, Bago-Horvath Z, Al-Zoughbi W, Hoefler G, Brostjan C, Gille L, Moriggl R, Spittler A, Sexl V, Hoelbl-Kovacic A.

Br J Haematol. 2017 Oct;179(2):229-241. doi: 10.1111/bjh.14833. Epub 2017 Jul 14.

5.

Opioids: Modulators of angiogenesis in wound healing and cancer.

Ondrovics M, Hoelbl-Kovacic A, Fux DA.

Oncotarget. 2017 Apr 11;8(15):25783-25796. doi: 10.18632/oncotarget.15419. Review.

6.

Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML.

Sadovnik I, Hoelbl-Kovacic A, Herrmann H, Eisenwort G, Cerny-Reiterer S, Warsch W, Hoermann G, Greiner G, Blatt K, Peter B, Stefanzl G, Berger D, Bilban M, Herndlhofer S, Sill H, Sperr WR, Streubel B, Mannhalter C, Holyoake TL, Sexl V, Valent P.

Clin Cancer Res. 2016 Apr 15;22(8):2051-61. doi: 10.1158/1078-0432.CCR-15-0767. Epub 2015 Nov 25.

7.

Modeling BCR/ABL-driven malignancies in the mouse.

Schneckenleithner C, Hoelbl-Kovacic A, Sexl V.

Methods Mol Biol. 2015;1267:263-82. doi: 10.1007/978-1-4939-2297-0_12.

PMID:
25636473
8.

CDK6 as a key regulator of hematopoietic and leukemic stem cell activation.

Scheicher R, Hoelbl-Kovacic A, Bellutti F, Tigan AS, Prchal-Murphy M, Heller G, Schneckenleithner C, Salazar-Roa M, Zöchbauer-Müller S, Zuber J, Malumbres M, Kollmann K, Sexl V.

Blood. 2015 Jan 1;125(1):90-101. doi: 10.1182/blood-2014-06-584417. Epub 2014 Oct 23. Erratum in: Blood. 2018 Aug 30;132(9):978-979.

9.

Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2.

Grundschober E, Hoelbl-Kovacic A, Bhagwat N, Kovacic B, Scheicher R, Eckelhart E, Kollmann K, Keller M, Grebien F, Wagner KU, Levine RL, Sexl V.

Leukemia. 2014 Sep;28(9):1918-22. doi: 10.1038/leu.2014.152. Epub 2014 May 5. No abstract available.

10.

Lactotransferrin-Cre reporter mice trace neutrophils, monocytes/macrophages and distinct subtypes of dendritic cells.

Kovacic B, Hoelbl-Kovacic A, Fischhuber KM, Leitner NR, Gotthardt D, Casanova E, Sexl V, Müller M.

Haematologica. 2014 Jun;99(6):1006-15. doi: 10.3324/haematol.2013.097154. Epub 2014 Feb 21.

11.

Loss of STAT3 in Lymphoma Relaxes NK Cell-Mediated Tumor Surveillance.

Putz EM, Hoelzl MA, Baeck J, Bago-Horvath Z, Schuster C, Reichholf B, Kern D, Aberger F, Sexl V, Hoelbl-Kovacic A.

Cancers (Basel). 2014 Jan 27;6(1):193-210. doi: 10.3390/cancers6010193.

12.

PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis.

Berger A, Hoelbl-Kovacic A, Bourgeais J, Hoefling L, Warsch W, Grundschober E, Uras IZ, Menzl I, Putz EM, Hoermann G, Schuster C, Fajmann S, Leitner E, Kubicek S, Moriggl R, Gouilleux F, Sexl V.

Leukemia. 2014 Mar;28(3):629-41. doi: 10.1038/leu.2013.351. Epub 2013 Nov 22.

13.

STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia.

Warsch W, Grundschober E, Berger A, Gille L, Cerny-Reiterer S, Tigan AS, Hoelbl-Kovacic A, Valent P, Moriggl R, Sexl V.

Oncotarget. 2012 Dec;3(12):1669-87.

Supplemental Content

Loading ...
Support Center